Nicotinamide (vitamin B3) has been shown to have protective effects against damage caused by UV radiation and to reduce the rate of new premalignant actinic keratosis and non-melanoma skin cancers.  Here are the numbers from the Study published in the New England Journal of Medicine:

  • 386 participants who had had at least two non-melanoma skin cancers in the previous 5 years received 500 mg of nicotinamide twice daily or placebo for 12 months.
  • The number of actinic keratoses at 4 months was 29% lower among those who received 500 mg of nicotinamide administered orally once daily and 35% lower among those who received 500 mg of nicotinamide twice daily than among those who received placebo.
  • Patients taking nicotinamide twice daily experienced a 25% decrease in non-melanoma skin cancer rates.

AboutSkin now has nicotinamide available for your convenience.  It retails for $29.50 + tax for 100 tablets.  We advise taking one table twice daily to maximize the health benefits.

If you want to read the entire study, here is the link:

http://www.nejm.org/doi/full/10.1056/NEJMoa1506197#t=article

For additional information, including interesting new research on how eating too much grapefruit may increase your risk for melanoma, read the following article:

http://dermatologytimes.modernmedicine.com/dermatology-times/news/more-light-shed-skin-disease?GUID=F8BCEE45-EF77-40D7-BF43-16E0CBD6D173&rememberme=1&ts=31072016

Patient Testimonials

Let Your Skin Glow

Let Your Skin Glow

Let Your Skin Glow

Let Your Skin Glow

Let Your Skin Glow

Tag us on Instagram @aboutskindermatology

Book Your Consultation Today

This field is for validation purposes and should be left unchanged.

By clicking submit you consent for us to contact you by phone, text or email using to the data provided, even if the contact info is on a state or national DNC list. You also consent to our Privacy Policy and Terms of Service.

Greenwood Village Office

5340 South Quebec ST., STE. 300 (South Entrance)
Greenwood Village, CO 80111

(303) 756-7546

Subscribe to our eblasts

This field is for validation purposes and should be left unchanged.